Fast Five Quiz: Plaque Psoriasis Management

William James, MD


July 09, 2021

Recent data suggest that biologic therapies for plaque psoriasis may improve coronary arteries by reducing noncalcified plaque and the necrotic core of plaque and increasing its fibrous cap, making it harder for plaques to rupture.

Like systemic agents, biologic therapies should be considered for patients with severe and refractory plaque psoriasis and for patients with active psoriatic arthritis.

Data suggest beneficial effects may be achieved by adding biologic therapy to methotrexate, with no additional toxicity.

Biologic therapies are designed to target key steps in the pathogenesis of plaque, including inhibiting the initial cytokine release and Langerhans cell migration. In addition, biologics block the interactions that lead to T-cell activation or migration into tissue; target activated T cells, prevent further T-cell activation, and eliminate pathologic T cells; alter the balance of T-cell types; and inhibit proinflammatory cytokines.

For additional information, refer to the Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis With Biologics, an expert consensus study from the National Psoriasis Foundation, and the guidelines of the British Association of Dermatologists.

Learn more about biologics for plaque psoriasis.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: